Having trouble viewing this email? View the online version.
ISSM logo

Latest News from the ISSM - January 2, 2015 Member Login
Researchers Study Udenafil

The phosphodiesterase type 5 (PDE5) inhibitor udenafil could improve cognition, depression, and somatization in men with erectile dysfunction (ED), Korean researchers say. 

Their study, published last spring in the International Journal of Impotence Research, built on previous work.

This study involved 60 men with a mean age of 60 years. The participants had had ED for an average of 16 to 18 months.

Half of the men took 50 mg of udenafil daily for eight weeks.  The other half took a placebo for the same duration.

Using a variety of assessment tools, including the International Index of Erectile Function (IIEF), the researchers evaluated the men at baseline and again at the eight-week point.

They found that the men taking udenafil had greater improvements in ED, depression, general cognition, depression, and somatization when compared to the placebo group.

Please click here for more information on this study.

Sexual Medicine - Discounted Publishing Rate Still Available for ISSM Members

For a limited time, ISSM members may publish in Sexual Medicine, the ISSM's open access journal, for $100.

This subsidy applies to 20 papers authored by ISSM members that are accepted for publication in Sexual Medicine. For eligible papers, ISSM members pay a special discounted rate of $100 (regularly $500).

This offer is available to ISSM members only. Please click here to submit your manuscript. More information about publishing in Sexual Medicine may be found here.

Further details about this program are available here.

You are receiving this newsletter because you are subscribed to our mailing list.
If you would rather not receive emails like this in the future you can unsubscribe.

ISSM | International Society for Sexual Medicine
P.O. Box 94 | 1520 AB Wormerveer | The Netherlands